CA2301378A1 - Stabilized pharmaceutical composition of a nonsteroidal anti-inflammatory agent and a prostaglandin - Google Patents

Stabilized pharmaceutical composition of a nonsteroidal anti-inflammatory agent and a prostaglandin Download PDF

Info

Publication number
CA2301378A1
CA2301378A1 CA002301378A CA2301378A CA2301378A1 CA 2301378 A1 CA2301378 A1 CA 2301378A1 CA 002301378 A CA002301378 A CA 002301378A CA 2301378 A CA2301378 A CA 2301378A CA 2301378 A1 CA2301378 A1 CA 2301378A1
Authority
CA
Canada
Prior art keywords
prostaglandin
nsaid
pharmaceutical composition
inflammatory agent
nonsteroidal anti
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002301378A
Other languages
French (fr)
Other versions
CA2301378C (en
Inventor
Aomar Ouali
Abul Kalam Azad
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pharmascience Inc
Original Assignee
Pharmascience Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmascience Inc filed Critical Pharmascience Inc
Publication of CA2301378A1 publication Critical patent/CA2301378A1/en
Application granted granted Critical
Publication of CA2301378C publication Critical patent/CA2301378C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Abstract

A pharmaceutical composition is provided for the oral administration of an NSAID and a prostaglandin. The composition is a solid dosage form wherein the NSAID is enterically coated and the prostaglandin is present along with an effective stabilizing amount of a prostaglandin stabilizing agent such as hydroxypropyl methylcellulose or polyvinylpyrrolidone. Exemplary dosage forms are bilayer tablets in which the prostaglandin is misoprostol and the NSAID is diclofenac, piroxicam, or a pharmaceutically acceptable salt thereof.
Methods for using the composition to treat NSAID-responsive conditions, disorders and diseases are provided as well.
CA002301378A 1999-03-22 2000-03-20 Stabilized pharmaceutical composition of a nonsteroidal anti-inflammatory agent and a prostaglandin Expired - Fee Related CA2301378C (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/273,692 1999-03-22
US09/273,692 US6183779B1 (en) 1999-03-22 1999-03-22 Stabilized pharmaceutical composition of a nonsteroidal anti-inflammatory agent and a prostaglandin

Publications (2)

Publication Number Publication Date
CA2301378A1 true CA2301378A1 (en) 2000-09-22
CA2301378C CA2301378C (en) 2005-07-26

Family

ID=23045012

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002301378A Expired - Fee Related CA2301378C (en) 1999-03-22 2000-03-20 Stabilized pharmaceutical composition of a nonsteroidal anti-inflammatory agent and a prostaglandin

Country Status (7)

Country Link
US (2) US6183779B1 (en)
EP (1) EP1162975B1 (en)
AT (1) ATE350040T1 (en)
AU (1) AU3269200A (en)
CA (1) CA2301378C (en)
DE (1) DE60032749T2 (en)
WO (1) WO2000056339A1 (en)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8022095B2 (en) 1996-08-16 2011-09-20 Pozen, Inc. Methods of treating headaches using 5-HT agonists in combination with long-acting NSAIDs
US6319519B2 (en) 1998-07-07 2001-11-20 Norton Healthcare Ltd. Anti-inflammatory pharmaceutical formulations
US6514525B2 (en) 1998-09-10 2003-02-04 Norton Healthcare Ltd Anti-inflammatory pharmaceutical formulations
US6387410B1 (en) * 1998-09-10 2002-05-14 Norton Healthcare Ltd Anti-inflammatory pharmaceutical formulations
JP2003510347A (en) * 1999-10-01 2003-03-18 ノートン ヘルスケアー リミテッド Anti-inflammatory drug preparation
US7198803B2 (en) * 2000-03-21 2007-04-03 Nippon Shinyaku Co., Ltd. Sustained release oral preparations
AR030557A1 (en) * 2000-04-14 2003-08-27 Jagotec Ag A TABLET IN MULTI-MAP OF CONTROLLED RELEASE AND TREATMENT METHOD
US20020035107A1 (en) * 2000-06-20 2002-03-21 Stefan Henke Highly concentrated stable meloxicam solutions
US20020192299A1 (en) * 2000-12-28 2002-12-19 Rajneesh Taneja Pharmaceutical compositions of a non-enteric coated proton pump inhibitor with a carbonate salt and bicarbonate salt combination
US20020177626A1 (en) 2001-01-19 2002-11-28 Cook Graham D. Treatment of sleep disturbances
US8206741B2 (en) 2001-06-01 2012-06-26 Pozen Inc. Pharmaceutical compositions for the coordinated delivery of NSAIDs
GB2380937A (en) * 2001-10-18 2003-04-23 David Ian Slovick Method of dispensing a plurality of medical substances into capsules
DE10161077A1 (en) * 2001-12-12 2003-06-18 Boehringer Ingelheim Vetmed Highly concentrated stable meloxicam solutions for needleless injection
GB2386817B (en) * 2002-02-20 2006-08-23 Walcom Animal Science Feed for fish and use therof
US8323692B2 (en) 2002-02-21 2012-12-04 Valeant International Bermuda Controlled release dosage forms
DK1476138T3 (en) * 2002-02-21 2012-02-20 Valeant Internat Barbados Srl Modified release formulations of at least one form of tramadol
US20050124699A1 (en) * 2002-07-02 2005-06-09 Wakamoto Pharmaceutical Co., Ltd. Drugs for treating or preventing disorders of corneal and/or conjunctival epithelial cells
US20040082618A1 (en) * 2002-07-03 2004-04-29 Rajneesh Taneja Liquid dosage forms of acid labile drugs
US8992980B2 (en) 2002-10-25 2015-03-31 Boehringer Ingelheim Vetmedica Gmbh Water-soluble meloxicam granules
US20040121004A1 (en) * 2002-12-20 2004-06-24 Rajneesh Taneja Dosage forms containing a PPI, NSAID, and buffer
US20070243251A1 (en) * 2002-12-20 2007-10-18 Rajneesh Taneja Dosage Forms Containing A PPI, NSAID, and Buffer
WO2004064815A1 (en) * 2003-01-21 2004-08-05 Smartrix Technologies Inc. Oral dosage formulation
ATE366105T1 (en) * 2003-03-03 2007-07-15 Sprl Franpharma STABILIZED PHARMACEUTICAL COMPOSITION CONTAINING AN NSAID AND A PROSTAGLANDIN
WO2004091579A1 (en) * 2003-04-16 2004-10-28 Pharmacia Corporation Stabilized prostaglandin formulation
US20050096311A1 (en) * 2003-10-30 2005-05-05 Cns Response Compositions and methods for treatment of nervous system disorders
EP1568369A1 (en) 2004-02-23 2005-08-31 Boehringer Ingelheim Vetmedica Gmbh Use of meloxicam for the treatment of respiratory diseases in pigs
DE102004021281A1 (en) * 2004-04-29 2005-11-24 Boehringer Ingelheim Vetmedica Gmbh Use of meloxicam formulations in veterinary medicine
DE102004030409A1 (en) * 2004-06-23 2006-01-26 Boehringer Ingelheim Vetmedica Gmbh New use of meloxicam in veterinary medicine
WO2006070406A1 (en) * 2004-12-29 2006-07-06 J.B. Chemicals & Pharmaceuticals Ltd Bilayer tablets of oxcarbazepine for controlled delivery and a process of preparation thereof
US20060177504A1 (en) * 2005-02-08 2006-08-10 Renjit Sundharadas Combination pain medication
US20070053868A1 (en) * 2005-03-08 2007-03-08 Banner Pharmacaps, Inc. Solvent system for enhancing the solubility of pharmaceutical agents
US20080187581A1 (en) * 2005-03-16 2008-08-07 Subhash Pandurang Gore Delivery System For Mulitple Drugs
US20070224259A1 (en) * 2005-09-21 2007-09-27 Gupta Anil K Anti-inflammatory pharmaceutical composition
SG166115A1 (en) * 2005-09-30 2010-11-29 Boehringer Ingelheim Vetmed Pharmaceutical preparation containing meloxicam
WO2007060540A1 (en) * 2005-11-25 2007-05-31 Aurobindo Pharma Limited Stable dosage forms of an antidepressant
BRPI0619868A8 (en) * 2005-12-16 2016-06-07 Hanmi Pharm Ind Co Ltd SOLID DISPERSION COMPRISING AN ACTIVE INGREDIENT HAVING A LOW COMPRESSED MELTING POINT FOR ORAL ADMINISTRATION COMPRISING THE SAME
US20070190139A1 (en) * 2006-02-13 2007-08-16 Intelgenx Corp. Delayed release pharmaceutical oral dosage form and method of making same
PL2124556T3 (en) 2006-10-09 2015-02-27 Charleston Laboratories Inc Pharmaceutical compositions
EP2167048B1 (en) 2007-05-30 2016-10-26 Wockhardt Limited A novel tablet dosage form
US20090012165A1 (en) * 2007-07-03 2009-01-08 Sucampo Ag Pharmaceutical combination of nsaid and prostaglandin compound
US8124126B2 (en) 2008-01-09 2012-02-28 Charleston Laboratories, Inc. Pharmaceutical compositions
US20090214648A1 (en) * 2008-02-15 2009-08-27 Malathi Kandakatla Pharmaceutical formulations comprising ibuprofen and diphenhydramine
WO2010020772A2 (en) * 2008-08-22 2010-02-25 Reckitt Benckiser Healthcare (Uk) Limited Improvements in or relating to compositions
EA201100313A1 (en) 2008-09-09 2011-10-31 Астразенека Аб METHOD OF DELIVERY OF THE PHARMACEUTICAL COMPOSITION TO THE PATIENT NEEDING THIS
US20100233259A1 (en) * 2008-12-12 2010-09-16 Pascal Grenier Dosage form of ropinirole
WO2010151697A1 (en) * 2009-06-25 2010-12-29 Pozen Inc. Method for treating a patient in need of aspirin therapy
AU2010263304A1 (en) 2009-06-25 2012-02-02 Astrazeneca Ab Method for treating a patient at risk for developing an NSAID-associated ulcer
WO2011006012A1 (en) 2009-07-08 2011-01-13 Charleston Laboratories Inc. Pharmaceutical compositions
AU2010307096B2 (en) * 2009-10-12 2014-07-03 Boehringer Ingelheim Vetmedica Gmbh Containers for compositions comprising meloxicam
WO2011107150A1 (en) 2010-03-03 2011-09-09 Boehringer Ingelheim Vetmedica Gmbh Use of meloxicam for the long-term treatment of musculoskeletal disorders in cats
US9795568B2 (en) 2010-05-05 2017-10-24 Boehringer Ingelheim Vetmedica Gmbh Low concentration meloxicam tablets
CN102336693B (en) * 2010-07-21 2014-01-22 上海天伟生物制药有限公司 Carboprost tromethamine crystals, preparation method and application thereof
EP2765999A4 (en) * 2011-10-14 2015-04-01 Purdue Research Foundation Ingestible multi-sheet unit having predetermined functions and combinations
WO2013101897A2 (en) 2011-12-28 2013-07-04 Pozen Inc. Improved compositions and methods for delivery of omeprazole plus acetylsalicylic acid
CN105435239B (en) * 2014-08-29 2019-04-26 武汉光谷人福生物医药有限公司 Mei Suoshuli Film coated tablets and preparation method thereof
US9839212B2 (en) 2015-04-16 2017-12-12 Bio-Lab, Inc. Multicomponent and multilayer compacted tablets
JP2019507181A (en) 2016-03-04 2019-03-14 チャールストン ラボラトリーズ，インコーポレイテッド Pharmaceutical composition

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3781429A (en) 1972-09-29 1973-12-25 American Cyanamid Co Method of inhibiting ulcerogenesis induced by non-steroidal anti-inflammatory agents
US3927213A (en) 1973-07-10 1975-12-16 American Home Prod Prostaglandin E{HD 2 {B and derivatives for reducing the side effects of anti-inflammatory agents
US3928588A (en) 1974-02-22 1975-12-23 Upjohn Co Method of reducing the undesirable gastrointestinal effects of prostaglandin synthetase inhibitors
US3954787A (en) 1974-06-18 1976-05-04 Pfizer Inc. Stabilized E-series prostaglandins
US4301146A (en) 1980-07-29 1981-11-17 G. D. Searle & Co. Stabilization of 16-oxygenated prostanoic acid derivatives
AU7876491A (en) 1990-05-03 1991-11-27 G.D. Searle & Co. Pharmaceutical composition
US5015481A (en) 1990-05-03 1991-05-14 G. D. Searle & Co. Stabilized pharmaceutical admixture composition
EA002806B1 (en) 1997-09-11 2002-10-31 Нюкомед Данмарк А/С Modified release multiple-units compositions of non-steroid anti-inflammatory drug substances (nsaid)
CA2241342C (en) 1998-06-15 2000-02-08 Bernard Charles Sherman Pharmaceutical tablets comprising an nsaid and a prostaglandin
GB9814215D0 (en) 1998-07-01 1998-09-02 Norton Healthcare Ltd Anti-inflammatory pharmaceutical formulations
GB9819685D0 (en) 1998-09-10 1998-11-04 Norton Healthcare Ltd Anti-inflammatory pharmaceutical formulations

Also Published As

Publication number Publication date
EP1162975A1 (en) 2001-12-19
DE60032749D1 (en) 2007-02-15
DE60032749T2 (en) 2007-10-18
US6183779B1 (en) 2001-02-06
AU3269200A (en) 2000-10-09
WO2000056339A1 (en) 2000-09-28
US6287600B1 (en) 2001-09-11
ATE350040T1 (en) 2007-01-15
EP1162975B1 (en) 2007-01-03
CA2301378C (en) 2005-07-26

Similar Documents

Publication Publication Date Title
CA2301378A1 (en) Stabilized pharmaceutical composition of a nonsteroidal anti-inflammatory agent and a prostaglandin
EP1218889B1 (en) Controlled release compositions comprising nimesulide
CA2389235A1 (en) Controlled release hydrocodone formulations
HUP0301591A2 (en) Controlled release hydrocodone compositions
JP2002502871A5 (en)
CA2601289A1 (en) Once-a-day oxycodone formulations
US20070184109A1 (en) Compositions comprising triptans and nsaids
JP2005512995A5 (en)
CA2481142A1 (en) Bisphosphonic acids for the treatment and prevention of osteoporosis
CA2315261A1 (en) Oral pharmaceutical extended release dosage form
EP1462098B1 (en) Stabilised pharmaceutical composition comprising a non-steroidal anti-inflammatory agent and a prostaglandin
WO2002024203A3 (en) Controlled release formulations for oral administration
CA2411882A1 (en) Solid valsartan pharmaceutical compositions
RU2003100507A (en) PHARMACEUTICAL COMPOSITIONS
BR0013719A (en) Controlled-release oral dosage, suitable for oral administration
AU4903700A (en) Chronotherapeutic diltiazem formulations and the administration thereof
JP2004505036A5 (en)
HUP0401429A2 (en) Pharmaceutical composition comprising lumiracoxib
WO2002011694A3 (en) Compositions and dosage forms for application in the oral cavity in the treatment of mykoses
CA2416771A1 (en) 5-methyl-2-(2'-chloro-6'-fluoroanilino)phenylacetic acid for treatment of cox-2 dependent disorders
CA2279184C (en) Pharmaceutical compositions containing ibuprofen and domperidone for the treatment of migraine
US20040204403A1 (en) Pharmaceutical composition comprising ibuprofen and prochlorperazine
JPH05246845A (en) Antipyretic analgesic agent containing ibuprofen
CA2514022A1 (en) Reduced dose of tolterodine and other antimuscarinic agents for treating urinary disorders
JP2003523385A5 (en)

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20140320